A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

NCT06186804 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

cGvHD

Interventions

DRUG: ABSK021

Sponsor

Abbisko Therapeutics Co, Ltd